Google answer:
Data from DURATION-1 demonstrated that continuous HbA1c reductions and weight loss were observed for the patients continuing on the treatment, with no unexpected adverse events. Taken together, these data support GLP-1RAs as a long-term noninsulin treatment option after the failure of oral therapy.
We are responsible to monitor for changes in client status…regular DEP visits and bloodwork as well as collaboration with PCP